Упрощенная HTML-версия
137
118.
Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a re-
sult of impaired calcium handling in isolated cardiac myocytes
/ A.
Maeda
[et al.] // Jpn. Circ. J. – 1998. – Vol. 62, № 7. – P. 505-511.
119.
Drug insight: statins for nonischemic heart failure – evidence and potential
mechanisms / M. J. Lipinski [et al.] // Nat. Clin. Pract. Cardiovasc. – 2007.
– Vol. 4, № 4. – P. 196-205.
120.
Effect of doxorubicin on diastolic function, contractive reserve and ven-
tricular-vascular coupling in piglets / S. C. Cassidy [et al.] // Pediatr. Car-
diol. – 1998. – Vol. 19, № 6. – P. 450-457.
121.
Endemann D. H. Endothelial dysfunction / D. H. Endemann, E. L. Schiffrin
// J. Am. Soc. Nephrol. – 2004. – Vol. 15. – P. 1983-1992.
122.
Experimental and clinical basis for the use of statins in patients with is-
chemic and nonischemic cardiomyopathy / K. Ramasubbu [et al.] // J. Am.
Coll. Cardiol. – 2008. – Vol. 51, № 4. – P. 415-426.
123.
Expert opinion on the use of anthracyclines in patients with advanced
breast cancer at cardiac risk / P. J. Barrett-Lee [et al.] // Ann. Oncol. –
2009. – Vol. 20, № 5. – P. 816-827.
124.
Fisher B. Biological and clinical considerations regarding the use of sur-
gery and chemotherapy in the treatment of primary breast cancer / B. Fisher
// Cancer. – 1977. – Vol. 40. – P. 574-587.
125.
TheBreastCancerAlternativeHypothesis [Электронныйресурс] / B. Fisher,
S.A.
Anderson
//
BreastCancer.-2010.-Режим
доступа:
126.
Foung Y. CASH (Chemotherapy-associated steatohepatitis) costs / Y.
Foung, D. J. Bentrem // Ann. Surg. – 2006. – Vol. 243, № 1. – Р. 8-9.
127.
Germanakis I. Troponin and natriuretic peptides in the Monitoring of antra-
cycline Cardiotoxicity / I. Germanakis, N. Anagnostatou, M. Kalmanti //
Pediatr. Blood Cancer. – 2008. – Vol. 51, № 3. – P. 327-333.
128.
Goldhirsch A. Cаrdiotoxicity: the view of the oncologist [Электронный-
ресурс]-2011.-Режимдоступа:http://cardiooncology.it.